Lung Cancer Screening and Prevention Act of 2025

The Lung Cancer Screening and Prevention Act of 2025 would expand Medicare coverage to include additional lung cancer screening tests beyond the current standard LDCT (low-dose computed tomography) screening. Specifically, it allows the Secretary of Health and Human Services to cover other screening tests for lung cancer that are FDA-cleared or FDA-approved as preventive services when used for appropriate individuals, with coverage frequency and payment limits set through consultation with relevant organizations. The decision on whether to cover these new tests would follow the national coverage determination process, but without the separate requirement tied to a specific 1861(ddd)(3)(B) determination. The bill also permits consideration of recommendations from preventive-services experts and entities convened by the Secretary or the Agency for Healthcare Research and Quality (AHRQ). The changes would take effect on enactment and apply to Part B preventive-services coverage from that date forward. In short, the bill modernizes and broadens Medicare’s preventive-screening toolkit for lung cancer by authorizing FDA-cleared/approved tests beyond the current program, while using established CMS processes and expert guidance to guide coverage and reimbursement decisions.